Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study

This open-label single-group study will give a single oral dose of PEX010 (psilocybin 25 mg) to 10 participants with alcohol use disorder to assess feasibility and safety.

Participants will meet with a psychologist for preparation and post-session debriefing; blood samples will be taken during the dosing session to establish psilocin pharmacokinetics and estimated 5-HT2A receptor occupancy, and outcomes including adverse events will be assessed at one week.